Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986340 · 1 trial · 11 indications
| Arm | Type | Description |
|---|---|---|
| Part 1A: BMS-986340 Dose Escalation | EXPERIMENTAL | - |
| Part 2A: BMS-986340 Dose Expansion | EXPERIMENTAL | - |
| Part 1B: BMS-986340 + Nivolumab Dose Escalation | EXPERIMENTAL | - |
| Part 2B: BMS-986340 + Nivolumab Dose Expansion | EXPERIMENTAL | - |
| Part 1C: BMS-986340 + Docetaxel Dose Escalation | EXPERIMENTAL | - |
| Part 1A-J: BMS-986340 Dose Escalation | EXPERIMENTAL | - |
| Part 1B-J: BMS-986340 + Nivolumab Dose Escalation | EXPERIMENTAL | - |
| Part 2C: BMS-986340 + Docetaxel Dose Expansion | EXPERIMENTAL | - |
| Part 2D: BMS-986340 + Pumitamig Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986340 | DRUG | Specified dose on specified days |
| BMS-936558-01 | DRUG | Specified dose on specified days |
| Docetaxel | DRUG | Specified dose on specified days |
| Pumitamig | DRUG | Specified dose on specified days |
Inclusion Criteria * Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are...
Top 20 of 26 competitors
BMS-986340 is an investigational small molecule being developed for the treatment of cervical cancer. It is also being studied in other advanced solid tumors, including gastric cancer, colorectal cancer, non-small-cell lung cancer, head and neck cancer, renal cell carcinoma, urothelial carcinoma, pancreatic cancer, melanoma, ovarian cancer, and triple-negative breast cancer.
BMS-986340 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is conducting clinical trials to evaluate the drug as a monotherapy and in combination with other treatments for advanced solid tumors.
BMS-986340 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and efficacy in patients with advanced solid tumors.
BMS-986340 is being studied in one active Phase 1 clinical trial with the identifier NCT04895709. This trial is recruiting participants with advanced solid tumors, including cervical cancer, and is evaluating the drug as a monotherapy and in combination therapy. The trial is enrolling up to 1,109 participants across multiple countries.
No alternative names for BMS-986340 have been reported. The drug is identified by its code name BMS-986340 in clinical trials and scientific literature. It is a distinct investigational compound being developed by Bristol-Myers Squibb for oncology indications.